Hsin‐Jung Wu

867 total citations
16 papers, 685 citations indexed

About

Hsin‐Jung Wu is a scholar working on Molecular Biology, Oncology and Clinical Biochemistry. According to data from OpenAlex, Hsin‐Jung Wu has authored 16 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Clinical Biochemistry. Recurrent topics in Hsin‐Jung Wu's work include Advanced Glycation End Products research (5 papers), DNA Repair Mechanisms (3 papers) and Curcumin's Biomedical Applications (3 papers). Hsin‐Jung Wu is often cited by papers focused on Advanced Glycation End Products research (5 papers), DNA Repair Mechanisms (3 papers) and Curcumin's Biomedical Applications (3 papers). Hsin‐Jung Wu collaborates with scholars based in United States, Taiwan and France. Hsin‐Jung Wu's co-authors include Wen‐Hsiung Chan, Jun‐Lin Guan, Nion‐Heng Shiao, Mingang Hao, Syn Kok Yeo, Yan‐Der Hsuuw, Shaogang Sun, Roger J. Davis, Chandrasekhar Venkataraman and Subbarao Bondada and has published in prestigious journals such as The Journal of Immunology, Cancer Research and Oncogene.

In The Last Decade

Hsin‐Jung Wu

16 papers receiving 671 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hsin‐Jung Wu United States	10	343	157	122	88	83	16	685
Uttam Pati India	23	641 1.9×	53 0.3×	229 1.9×	73 0.8×	251 3.0×	40	1.1k
Siriporn Keeratichamroen Thailand	13	268 0.8×	60 0.4×	89 0.7×	36 0.4×	119 1.4×	23	492
Laura Conde de la Rosa United States	18	515 1.5×	42 0.3×	150 1.2×	65 0.7×	244 2.9×	23	1.3k
Xiongxiong Liu China	15	578 1.7×	41 0.3×	184 1.5×	89 1.0×	120 1.4×	34	999
Michelle L. Boland United States	11	852 2.5×	44 0.3×	274 2.2×	71 0.8×	90 1.1×	15	1.4k
Kang-Sik Seo South Korea	12	341 1.0×	29 0.2×	174 1.4×	53 0.6×	56 0.7×	23	731
Kirit Pindolia United States	17	347 1.0×	16 0.1×	68 0.6×	89 1.0×	77 0.9×	28	712
Xu Zheng China	19	516 1.5×	20 0.1×	99 0.8×	97 1.1×	166 2.0×	50	924
Ajda Çoker Gürkan Türkiye	19	502 1.5×	13 0.1×	124 1.0×	107 1.2×	181 2.2×	69	914
Gi‐Ryang Kweon South Korea	17	478 1.4×	23 0.1×	243 2.0×	72 0.8×	65 0.8×	26	1.0k

Countries citing papers authored by Hsin‐Jung Wu

Since Specialization

Citations

This map shows the geographic impact of Hsin‐Jung Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hsin‐Jung Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hsin‐Jung Wu more than expected).

Fields of papers citing papers by Hsin‐Jung Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hsin‐Jung Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hsin‐Jung Wu. The network helps show where Hsin‐Jung Wu may publish in the future.

Co-authorship network of co-authors of Hsin‐Jung Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Hsin‐Jung Wu. A scholar is included among the top collaborators of Hsin‐Jung Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hsin‐Jung Wu. Hsin‐Jung Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Simoneau, Antoine, R Swain, Serge Gueroussov, et al.. (2025). Abstract B039: APEX2 is a synthetic lethal target for RNASEH2B-deleted or BRCA-mutant tumors. Molecular Cancer Therapeutics. 24(10_Supplement). B039–B039. 1 indexed citations

Simoneau, Antoine, Hsin‐Jung Wu, Charlotte Pratt, et al.. (2024). Abstract 4527: TNG348 is synergistic with PARP inhibitors in tumor models with elevated replication stress. Cancer Research. 84(6_Supplement). 4527–4527. 1 indexed citations

House, Nealia C., et al.. (2023). CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination. NAR Cancer. 5(3). zcad039–zcad039. 15 indexed citations

Simoneau, Antoine, Charlotte Pratt, Hsin‐Jung Wu, et al.. (2023). Abstract B054: TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repair. Molecular Cancer Therapeutics. 22(12_Supplement). B054–B054. 5 indexed citations

House, Nealia C., Karen J. Ho, Hsin‐Jung Wu, et al.. (2023). Abstract P6-10-07: CDK2 inhibition with BLU-222 in combination with ribociclib demonstrates robust antitumor activity in pre-clinical models of CDK4/6 inhibitor-naïve and -resistant HR+/HER2- breast cancer. Cancer Research. 83(5_Supplement). P6–10. 8 indexed citations

Ichikawa, Kana, Ammar Adam, Hsin‐Jung Wu, et al.. (2022). 888 Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models. Regular and Young Investigator Award Abstracts. A925–A925. 2 indexed citations

Wu, Hsin‐Jung, Mingang Hao, Syn Kok Yeo, & Jun‐Lin Guan. (2020). FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication. Oncogene. 39(12). 2539–2549. 133 indexed citations

Sun, Shaogang, Hsin‐Jung Wu, & Jun‐Lin Guan. (2018). Nuclear FAK and its kinase activity regulate VEGFR2 transcription in angiogenesis of adult mice. Scientific Reports. 8(1). 2550–2550. 48 indexed citations

Sehdev, Amikar, Olumide B. Gbolahan, Bradley A. Hancock, et al.. (2018). Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic ductal adenocarcinoma patients treated with FOLFIRINOX. Annals of Oncology. 29. viii242–viii242. 1 indexed citations

10.

Chan, Wen‐Hsiung & Hsin‐Jung Wu. (2007). Methylglyoxal and high glucose co‐treatment induces apoptosis or necrosis in human umbilical vein endothelial cells. Journal of Cellular Biochemistry. 103(4). 1144–1157. 57 indexed citations

11.

Chan, Wen‐Hsiung & Hsin‐Jung Wu. (2006). Protective effects of curcumin on methylglyoxal-induced oxidative DNA damage and cell injury in human mononuclear cells. Acta Pharmacologica Sinica. 27(9). 1192–1198. 31 indexed citations

12.

Chan, Wen‐Hsiung, Hsin‐Jung Wu, & Nion‐Heng Shiao. (2006). Apoptotic signaling in methylglyoxal‐treated human osteoblasts involves oxidative stress, c‐Jun N‐terminal kinase, caspase‐3, and p21‐activated kinase 2. Journal of Cellular Biochemistry. 100(4). 1056–1069. 138 indexed citations

13.

Wu, Hsin‐Jung & Wen‐Hsiung Chan. (2006). Genistein protects methylglyoxal-induced oxidative DNA damage and cell injury in human mononuclear cells. Toxicology in Vitro. 21(3). 335–342. 43 indexed citations

14.

Chan, Wen‐Hsiung, Hsin‐Jung Wu, & Yan‐Der Hsuuw. (2005). Curcumin Inhibits ROS Formation and Apoptosis in Methylglyoxal‐Treated Human Hepatoma G2 Cells. Annals of the New York Academy of Sciences. 1042(1). 372–378. 92 indexed citations

15.

Chan, Wen‐Hsiung & Hsin‐Jung Wu. (2004). Anti‐apoptotic effects of curcumin on photosensitized human epidermal carcinoma A431 cells. Journal of Cellular Biochemistry. 92(1). 200–212. 78 indexed citations

16.

Wu, Hsin‐Jung, Chandrasekhar Venkataraman, Steven Estus, et al.. (2001). Positive Signaling Through CD72 Induces Mitogen-Activated Protein Kinase Activation and Synergizes with B Cell Receptor Signals to Induce X-Linked Immunodeficiency B Cell Proliferation. The Journal of Immunology. 167(3). 1263–1273. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact